NSE ScannerComparison · NSE · data 2026-10-31
Beta Drugs Ltd. vs Sakar Healthcare Ltd
In plain words
Size: Sakar Healthcare Ltd is about 1 times the market value of Beta Drugs Ltd..
Valuation (P/E): Sakar Healthcare Ltd 49 vs Beta Drugs Ltd. 36.9.
Return on equity: Beta Drugs Ltd. 18.8% vs Sakar Healthcare Ltd 10%.
Profit growth over 3 years: Sakar Healthcare Ltd 33.7% a year vs Beta Drugs Ltd. 10.5% a year.
Debt to equity: Beta Drugs Ltd. 0.62 vs Sakar Healthcare Ltd 0.17.
Differences in the numbers, not a recommendation of either stock.
Side by side
| BETA | SAKAR | |
|---|---|---|
| Price | ₹1,798.4 | ₹944.8 |
| Market cap | ₹2,000 cr | ₹2,074 cr |
| P/E | 36.9 | 49 |
| P/B | 4.6 | 6.1 |
| ROE | 18.8% | 10.0% |
| ROCE | 16.6% | 12.4% |
| Debt / equity | 0.62 | 0.17 |
| Operating margin | 16.7% | 21.5% |
| Dividend yield | 0.00% | 0.00% |
| Sales growth, 3 years (yearly) | 19.2% | 23.6% |
| Profit growth, 3 years (yearly) | 10.5% | 33.7% |
| 1-year return | -4.8% | 167.0% |
| Revenue, last 12 months | ₹444 cr | ₹302 cr |
| Net profit, last 12 months | ₹52 cr | ₹43 cr |
| Latest quarter | Sept 2026 | — |
| Quarter net profit | ₹20 cr | — |
| Quarter profit vs a year earlier | — | — |
| Promoter holding | 58.91% | 51.70% |
| Health check | Strong (6.5/10) | Strong (7.1/10) |
Common questions
Which has a higher P/E, Beta Drugs Ltd. or Sakar Healthcare Ltd?
Sakar Healthcare Ltd trades at the higher P/E (49 against 36.9). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Beta Drugs Ltd. (18.8% against 10.0%).
Which carries more debt?
Beta Drugs Ltd. has the higher debt-to-equity ratio (0.62 against 0.17).